Cetera Advisor Networks LLC Esperion Therapeutics, Inc. Transaction History

Cetera Advisor Networks LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.73 - $3.08 $556 - $2,346	-762 Reduced 5.75%	12,500 $37,000
Q2 2023 Aug 09, 2023	BUY	$1.2 - $1.76 $404 - $593	337 Added 2.61%	13,262 $18,000
Q4 2021 Feb 14, 2022	SELL	$4.81 - $11.92 $480 - $1,192	-100 Reduced 0.77%	12,925 $65,000
Q3 2021 Nov 16, 2021	BUY	$11.34 - $21.37 $33,736 - $63,575	2,975 Added 29.6%	13,025 $157,000
Q2 2021 Aug 13, 2021	BUY	$19.4 - $28.71 $1,455 - $2,153	75 Added 0.75%	10,050 $213,000
Q1 2021 May 17, 2021	SELL	$25.12 - $36.89 $9,420 - $13,833	-375 Reduced 3.62%	9,975 $280,000
Q4 2020 Feb 17, 2021	SELL	$24.2 - $35.76 $12,100 - $17,880	-500 Reduced 4.61%	10,350 $269,000
Q3 2020 Nov 13, 2020	SELL	$31.18 - $52.71 $35,857 - $60,616	-1,150 Reduced 9.58%	10,850 $403,000
Q2 2020 Aug 13, 2020	BUY	$30.04 - $51.31 $142,780 - $243,876	4,753 Added 65.59%	12,000 $616,000
Q1 2020 May 08, 2020	BUY	$27.44 - $73.84 $105,506 - $283,914	3,845 Added 113.02%	7,247 $228,000
Q4 2019 Feb 10, 2020	BUY	$35.4 - $59.82 $120,430 - $203,507	3,402 New	3,402 $203,000

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $171M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.